Literature DB >> 12893644

Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation.

Dorisanne D Miller1, Mohammad M Amin, Lucy B Palmer, Akbar R Shah, Gerald C Smaldone.   

Abstract

Aerosol delivery via a mechanical ventilator remains unregulated with no standards for drug delivery to intubated patients. Bench models predicting drug delivery have not been validated in vivo. For modern ventilator designs, we chose to identify, on the bench, the most important variables affecting aerosol delivery and to correlate in vitro predictions of aerosol delivery with in vivo end points independent of patient response. Test aerosols of albuterol and antibiotics were compared. Bench measurements of inhaled mass (percentage of nebulizer charge, mean +/- SEM) ranged from 5.7 +/- 0.5% to 37.4 +/- 1.6%, with breath-actuated nebulization and humidity identified as the most important factors determining aerosol delivery. In patients, sputum levels of deposited antibiotics varied from 1.10 to 19.6 microg/ml/mg. Variation in sputum levels correlated with predictions from the in vitro model. Aerosol delivery in ventilated patients can be efficient and reproducible only if defined ventilator parameters are tightly controlled. Key parameters can be determined via in vitro bench testing defining delivery standards for clinical trials of drugs with narrow therapeutic/toxicity ratios.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12893644     DOI: 10.1164/rccm.200210-1167OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  39 in total

1.  Application of an inline dry powder inhaler to deliver high dose pharmaceutical aerosols during low flow nasal cannula therapy.

Authors:  Dale Farkas; Michael Hindle; P Worth Longest
Journal:  Int J Pharm       Date:  2018-05-05       Impact factor: 5.875

Review 2.  Aerosol delivery to ventilated newborn infants: historical challenges and new directions.

Authors:  Jan Mazela; Richard A Polin
Journal:  Eur J Pediatr       Date:  2010-09-28       Impact factor: 3.183

Review 3.  Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia.

Authors:  G Christopher Wood; Joseph M Swanson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Comparison of lung tissue concentrations of nebulized ceftazidime in ventilated piglets: ultrasonic versus vibrating plate nebulizers.

Authors:  Fabio Ferrari; Zhi-Hai Liu; Qin Lu; Marie-Helene Becquemin; Kamel Louchahi; Guy Aymard; Charles-Hugo Marquette; Jean-Jacques Rouby
Journal:  Intensive Care Med       Date:  2008-04-30       Impact factor: 17.440

5.  Inhaled antimicrobial therapies for respiratory infections.

Authors:  Shin-Woo Kim; Joseph L Kuti; David P Nicolau
Journal:  Curr Infect Dis Rep       Date:  2008-03       Impact factor: 3.725

Review 6.  Aerosol delivery via invasive ventilation: a narrative review.

Authors:  Hui-Ling Lin; James B Fink; Huiqing Ge
Journal:  Ann Transl Med       Date:  2021-04

Review 7.  Inhaled antibiotics during mechanical ventilation-why it will work.

Authors:  Maxime Desgrouas; Stephan Ehrmann
Journal:  Ann Transl Med       Date:  2021-04

8.  Aerosol therapy during mechanical ventilation: an international survey.

Authors:  Stephan Ehrmann; Ferran Roche-Campo; Giuseppe Francesco Sferrazza Papa; Daniel Isabey; Laurent Brochard; Gabriela Apiou-Sbirlea
Journal:  Intensive Care Med       Date:  2013-03-23       Impact factor: 17.440

9.  Optimal delivery of aerosols to infants during mechanical ventilation.

Authors:  P Worth Longest; Mandana Azimi; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-12-03       Impact factor: 2.849

10.  Aerosol delivery by an ultrasonic nebulizer during different mechanical ventilation settings in a lung model--a pilot study.

Authors:  Michael Winterhalter; Michael Bund; Nawid Khaladj; Christian Hagl; Andre Simon; Ludwig Hoy; Siegfried Piepenbrock; Niels Rahe-Meyer
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.